Other anti-cancer treatments, such as doxorubicin, synthetic triterpenoids, and peroxisome proliferator-activated receptor-γ (PPARγ) ligands, can also decrease FLIP expression as a side effect, therefore increasing sensitivity to death receptor-mediated cytotoxicity (140–142). This evidence concerns the gene CFLAR and cancer.